Close

What are ADC's

Our services

ADC Review
is made possible by:




NCT00233909 (Clinical Trial / Gemtuzumab Ozogamicin)

Study Title
A Trial of Gemtuzumab Ozogamicin (GO) in Combination With Zosuquidar in Patients With CD33 Positive Acute Myeloid Leukemia (NCT00233909)

Trial Description
Chemotherapy drugs use different ways to stop cancer cells from dividing so they stop growing or die. The P-glycoprotein inhibitors Zosuquidar (also known as LY 335979; RS 33295; RS 33295-198; Zosuquidar trihydrochloride) may help gemtuzumab ozogamicin (Mylotarg®; Pfizer/Wyeth-Ayerst Laboratories) kill more cancer cells by making cancer cells more sensitive to the drug. It is not known whether Gemtuzumab Ozogamicin (GO) is more effective with or without zosuquidar in treating acute myeloid leukemia (AML).

This trial is sponsored by Kanisa Pharmaceuticals, Inc. [1]

Study Data

  • Condition: Myeloid Leukemia
  • Interventions:
  • Phase: I & II
  • Estimated Enrollment: 55
  • Start: October 2005
  • Completion: March 2008
  • Last verified: March 2008

Study Schematic

(Coming soon)

Click here to Return to Drug map


* The investigational drug zosuquidar trihydrochloride (a difluorocyclopropyl quinoline), which modulates P-glycoprotein (P-gp) with minimal delay of anthracycline clearance, may reverse P-gp-mediated multi-drug resistance (MDR) in acute myeloid leukemia (AML) without increased toxicity. P-glycoprotein, encoded by the MDR-1 gene, is a member of the ATP-binding cassette superfamily of transmembrane transporters and prevents the intracellular accumulation of many natural product-derived cytotoxic agents.

Last Editorial review: July 21, 2015
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.

Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.


Share

Recommended Articles

Four Ways to Show Nonobviousness of ADC Inventions

05 October, 2018

When the first antibody-drug conjugate (ADC) was approved by the U.S. Food and Drug Administration (FDA) in 2000,[1] only a handful of patent applications claiming ADCs had been published.[2] As research cont...


Skip to toolbar